Table 1.
Clinical HIV-1 vaccine efficacy trials. MSM, men who have sex with men. Ad5, adenovirus serotype 5.
| Study | Vaccines | Phase | Risk Group | HIV incidence per 100 person-years | Location | Result |
|---|---|---|---|---|---|---|
| Vax003 | AIDSVAX B/E gp120 in alum | III | Injecting drug users | 3.40% | Thailand | No vaccine efficacy |
| Vax004 | AIDSVAX B/B gp120 in alum | III | High risk women and MSM | 2.60% | United States, Europe | No vaccine efficacy |
| HVTN 502 Step |
MRKAd5 HIV-1 gag/pol/nef B | IIb | High risk women and MSM | 3.00% | United States | Halted at interim analysis for futility; early transient increased infection in vaccinees |
| HVTN 503 Phambili |
MRKAd5 HIV-1 gag/pol/nef B | IIb | High risk heterosexual men and women | 3.70% | South Africa | No vaccine efficacy; late increased HIV infection in unblinded male vaccinees |
| RV144 | ALVAC-HIV vCP1521, AIDSVAX B/E rgp120 in alum | III | Community risk heterosexual men and women | 0.28% | Thailand | 31.2% efficacy at 42 months as primary endpoint; 60% efficacy at 12 months |
| HVTN 505 | DNA, rAd5 (A, B, C) | IIb | Circumcised MSM without preexisting Ad5 antibodies | 1.80% | United States | Halted at interim analysis for futility |